---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-127067"
form_type: "8-K"
ticker: "PSTV"
cik: "0001095981"
company_name: "PLUS THERAPEUTICS, INC."
filed_at: "2024-11-14T23:59:59+00:00"
generated_at: "2026-05-30T00:14:11.728591+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Plus Therapeutics Q3 net loss $9.1M, cash $4.8M; FDA clears Phase 1 LM trial

## Summary
- Net loss YTD Sep 30, 2024: $9.1M ($1.46 basic EPS) vs $9.5M ($3.54) prior year; operating loss $10.8M vs $9.5M.
- Cash and investments $4.8M at Sep 30, down from $8.6M at Dec 31, 2023; subsequent $0.9M DoD grant, $3.9M CPRIT grant expected.
- FDA agreed to initiate Phase 1 multi-dose trial of Rhenium(186Re) Obisbemeda for leptomeningeal metastases (LM); enrollment starts early 2025 at 7 U.S. sites.
- Completed enrollment in ReSPECT-GBM Phase 1 trial; presented positive data at CNS 2024; expanded sites to North Shore and Ohio State.
- Established GMP manufacturing partnership with SpectronRx for late-stage clinical and commercial supply of Rhenium(186Re) Obisbemeda.

## SEC filing metadata
- accession: 0000950170-24-127067
- form_type: 8-K
- ticker: PSTV
- cik: 0001095981
- company_name: PLUS THERAPEUTICS, INC.
- filed_at: 2024-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/0000950170-24-127067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1095981/000095017024127067/pstv-20241114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-127067
- JSON: https://secwatch.observer/filing/0000950170-24-127067.json
- Plain text: https://secwatch.observer/filing/0000950170-24-127067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.